Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABCAMRF 81 EV-to-OCF is 40.33 as of Jul. 17, 2026. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $61.82 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Camurus AB ranks worse than 94.19% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Camurus AB's Enterprise Value is $3,494.6 Mil.
Camurus AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $86.7 Mil. Therefore, Camurus AB's EV-to-OCF for today is 40.33.
The historical rank and industry rank for Camurus AB's EV-to-OCF or its related term are showing as below:
CAMRF'
s EV-to-OCF Range Over the Past 10 Years
Min: -360.35 Med: -12.15 Max: 821.59
Current: 41.93
During the past 13 years, the highest EV-to-OCF of Camurus AB was 821.59. The lowest was -360.35. And the median was -12.15.
CAMRF's EV-to-OCF is ranked worse than 94.19% of 1411
companies
in the Biotechnology industry
Industry Median: -3.28
vs CAMRF: 41.93
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Camurus AB's share price for today is $58.51.
Camurus AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.204.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Camurus AB EV-to-OCF Related Terms
Camurus AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Camurus AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camurus AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Camurus AB's EV-to-OCF falls into.
Camurus AB's current Enterprise Value is $3,494.6 Mil.
Camurus AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $86.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a EV-to-OCF of 40.33 as of Jul. 17, 2026. According to the industry distribution chart, Camurus AB ranks #1329 out of 1411 companies in the Biotechnology industry, placing it in the top 94.2%.
Is Camurus AB's EV-to-OCF too high?
Camurus AB's current EV-to-OCF is 40.33. Based on the distribution chart, Camurus AB ranks #1329 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #1329 out of 1411 companies for EV-to-OCF. This places Camurus AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Camurus AB's current EV-to-OCF is 40.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Fairly Valued. The stock's GF Value™ is $61.82, compared to a current price of $58.51 — trading 5.4% below its estimated fair value. The current EV-to-OCF is 40.33. Camurus AB's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Camurus AB (CAMRF), the current EV-to-OCF is 40.33 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $58.51 is trading 5.4% below its estimated GF Value™ of $61.82.
GuruFocus considers Camurus AB to be Fairly Valued.
Key valuation signals for CAMRF:
EV-to-OCF: 40.33
GF Value™: $61.82 vs. price of $58.51 (5.4% below fair value)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
